Literature DB >> 24706152

Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends.

Nicolaas C Budhiparama1, Matthew P Abdel, Nadia N Ifran, Sébastien Parratte.   

Abstract

Venous thromboembolism (VTE) has been identified as an immediate threat to patients undergoing major orthopedic procedures such as total hip arthroplasty (THA) and total knee arthroplasty (TKA). Given the known dangers of VTE, arthroplasty surgeons are sensitive to the need for VTE thromboprophylaxis. However, the modalities of thromboprophylaxis used to minimize the risks to patients have been variable. Clinical practice guidelines have been published by several professional organizations, while some hospitals have established their own protocols. The 2 most popular guidelines are those published by the Academy of Orthopaedic Surgeons (AAOS) and American College of Chest Physicians (ACCP), both from North America. Prior to 2012, these recommendations varied depending on underlying definitions, methodology, and goals of the 2 groups. For the first time, both groups have similar recommendations that focus on minimizing symptomatic VTE and bleeding complications. The key to determining the appropriate chemoprophylaxis for patients is to balance efficacy of a prophylactic agent, while being safe in regards to bleeding complications. However, a multimodal approach that focuses on early postoperative mobilization and the use of mechanical prophylaxis, in addition to chemoprophylaxis, is essential.

Entities:  

Year:  2014        PMID: 24706152      PMCID: PMC4092192          DOI: 10.1007/s12178-014-9207-1

Source DB:  PubMed          Journal:  Curr Rev Musculoskelet Med        ISSN: 1935-9748


  65 in total

1.  Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.

Authors:  R H Fitzgerald; T E Spiro; A A Trowbridge; G A Gardiner; T L Whitsett; M B O'Connell; J A Ohar; T R Young
Journal:  J Bone Joint Surg Am       Date:  2001-06       Impact factor: 5.284

2.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

3.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Authors:  K A Bauer; B I Eriksson; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

4.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

5.  RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.

Authors: 
Journal:  J Bone Joint Surg Am       Date:  1994-08       Impact factor: 5.284

6.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

7.  A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.

Authors:  R Hull; G Raskob; G Pineo; D Rosenbloom; W Evans; T Mallory; K Anquist; F Smith; G Hughes; D Green
Journal:  N Engl J Med       Date:  1993-11-04       Impact factor: 91.245

8.  Surgical treatment of early wound complications following primary total knee arthroplasty.

Authors:  Daniel D Galat; Scott C McGovern; Dirk R Larson; Jeffrey R Harrington; Arlen D Hanssen; Henry D Clarke
Journal:  J Bone Joint Surg Am       Date:  2009-01       Impact factor: 5.284

9.  Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?

Authors:  Kevin J Bozic; Thomas P Vail; Penelope S Pekow; Judith H Maselli; Peter K Lindenauer; Andrew D Auerbach
Journal:  J Arthroplasty       Date:  2009-08-12       Impact factor: 4.757

10.  Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement.

Authors:  George Dranitsaris; Valentina Jelincic; Yoonhee Choe
Journal:  Thromb J       Date:  2011-01-27
View more
  6 in total

1.  What Is the State of Quality Measurement in Spine Surgery?

Authors:  Chase Bennett; Grace Xiong; Serena Hu; Kirkham Wood; Robin N Kamal
Journal:  Clin Orthop Relat Res       Date:  2018-04       Impact factor: 4.176

2.  Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis.

Authors:  Brandon R Hood; Mark E Cowen; Huiyong T Zheng; Richard E Hughes; Bonita Singal; Brian R Hallstrom
Journal:  JAMA Surg       Date:  2019-01-01       Impact factor: 14.766

3.  Perioperative Blood Transfusions Are Associated with a Higher Incidence of Thromboembolic Events After TKA: An Analysis of 333,463 TKAs.

Authors:  Alexander J Acuña; Daniel Grits; Linsen T Samuel; Ahmed K Emara; Atul F Kamath
Journal:  Clin Orthop Relat Res       Date:  2021-03-01       Impact factor: 4.755

4.  Safety and efficacy of a new thromboprophylaxis regiment for total knee and total hip replacement: a retrospective cohort study in 265 patients.

Authors:  Mohammad Amre Fallaha; Sarkhell Radha; Sheena Patel
Journal:  Patient Saf Surg       Date:  2018-08-14

5.  Optimal duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Association (NARA) group.

Authors:  Alma B Pedersen; Ina Trolle Andersen; Soren Overgaard; Anne Marie Fenstad; Stein Atle Lie; Jan-Erik Gjertsen; Ove Furnes
Journal:  Acta Orthop       Date:  2019-05-07       Impact factor: 3.717

6.  Non-compliance with clinical guidelines increases the risk of complications after primary total hip and knee joint replacement surgery.

Authors:  Helen Mary Badge; Tim Churches; Justine M Naylor; Wei Xuan; Elizabeth Armstrong; Leeanne Gray; John Fletcher; Iain Gosbell; Christine Lin; Ian A Harris
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.